UMN Pharma Inc. today announced initiation of phase II clinical trials with UMN-0501, UMN's avian influenza A (H5N1) vaccine manufactured by cell-culture.The purpose of this clinical study is to evaluate immunogenicity, safety and optimal dose in 90 healthy young adults aged 20-40. Study results will be obtained by next February.  For more information, please see here.